The emergence of new SARS-CoV-2 variants and the dangers of long-covid necessitate the
development of broad-acting therapeutics that can reduce viral burden. SARS-CoV-2
employs heparan sulfate (HS) as an initial cellular attachment factor, and therefore,
there is interest in developing heparin as a therapeutic for SARS-CoV-2. Its use is,
however, complicated by structural heterogeneity and the risk of causing bleeding and
thrombocytopenia. Here, we describe the preparation of well-defined heparin mimetics by
a controlled head-to-tail assembly of HS oligosaccharides having an alkyne or azide
moiety by copper-catalyzed azide-alkyne cycloaddition (CuAAC). Alkyne- and
azide-containing sulfated oligosaccharides were prepared from a common precursor by
modifying an anomeric linker with 4-pentynoic acid and by enzymatic extension with an
N
-acetyl-glucosamine having an azide moiety at C-6
(GlcNAc6N
3
), respectively, followed by CuAAC. The process of enzymatic
extension with GlcNAc6N
3
followed by CuAAC with the desired alkyne-containing
oligosaccharides could be repeated to give compounds composed of 20 and 27
monosaccharides, respectively. The heparin mimetics could inhibit the binding of the
SARS-CoV-2 spike or RBD to immobilized heparin or to Vero E6 cells. The inhibitory
potency increased with increasing chain length, and a compound composed of four sulfated
hexasaccharides linked by triazoles had a similar potency as unfractionated heparin.
Sequence analysis and HS microarray binding studies with a wide range of RBDs of
variants of concern indicate that they have maintained HS-binding capabilities and
selectivities. The heparin mimetics exhibit no or reduced binding to antithrombin-III
and platelet factor 4, respectively, which are associated with side effects.